ELEMENT-SIX
21.9.2021 01:03:08 CEST | Business Wire | Press release
Element Six, part of the De Beers Group, has launched DNV-B14™, its newest general-purpose chemical vapour deposition (CVD) quantum-grade diamond, an ideal material for quantum technologies such as magnetic field devices, RF sensors, solid-state gyroscopes and room temperature masers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005612/en/
The latest solution in Element Six’s DNV™ Series, DNV-B14™ expands the company’s range of advanced materials for emerging quantum technologies. Diamond containing nitrogen-vacancy (NV) centres offers researchers a unique solid-state platform with spin qubits that can be initialised and read out at room temperature, with long qubit lifetimes. These properties stem from diamond’s unique structure and strong bonds.
DNV-B14™ is designed to provide the end-user with a uniform and high density of NV spin centres - more than a 10-fold increase in NV density compared to DNV-B1™, the first material in the DNV™ Series. Launched last year, DNV-B1™ was winner of the SPIE Prism Award in the Quantum category in March 2021.
The combination of its engineered properties makes DNV-B14™ an ideal solution for experimentation and development of a range of technologies, such as ensemble NV-based vector magnetometry and room-temperature masers.
Dr Daniel Twitchen, Chief Technologist, commented, “Element Six’s founder, Sir Ernest Oppenheimer said no great industry can exist or develop without fundamental research. The DNV™ Series represents exactly that, with sustained R&D within our CVD team spanning over ten years and working across an eco-system that includes large companies, start-ups and some of the world’s leading Universities”.
Element Six diamond with NV densities comparable to DNV-B14™ has already been utilised in the development of high-sensitivity fibre-coupled magnetometers . Without the need for cumbersome cooling equipment, such devices can be made compact, and even portable. They are the ideal enabler of medical diagnostic techniques such as magnetocardiography (MCG) and magnetoencephalography (MEG).
Element Six’s engineered diamond research has also accelerated the delivery of many other breakthroughs in quantum research, including in 2018, when Imperial College London utilised engineered single crystal material in the development of the world’s first continuous-wave, room-temperature, solid-state maser (the microwave equivalent of a laser). Lockheed Martin’s 2019 Dark Ice program also relies on a DNV-enabled magnetometer that measures the direction and strength of nearly imperceptible magnetic field anomalies, opening up new possibilities in GPS-denied navigation.
- ENDS -
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005612/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
HyperLight Introduces 145 GHz Reference Modulators to Enable 448Gbps per Lane Datacom and 260GBaud Telecom Development12.3.2026 14:03:00 CET | Press release
HyperLight Corporation, creator of the TFLN Chiplet™ platform, today announced the release of its 145 GHz Packaged Intensity Modulator (IM), expanding the company‘s high-speed modulator portfolio. The new device is designed for ultra-wide modulation bandwidth, high signal fidelity, and stable operation control, enabling 448 Gbps per lane intensity-modulated-direct-detection (IMDD), 260 GBaud coherent links, and broadband RF photonics systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312319685/en/ Fig. 1: HyperLight’s 145 GHz intensity modulator for 448Gbps per lane IMDD and 260GBaud coherent applications, with operational electro-optical bandwidth >145GHz, stable bias control, 0.8 mm-connector; available in O-, C-, and L-bands. As symbol rates and analog bandwidth requirements continue to rise across data center interconnects, AI-driven photonics infrastructure, and laboratory test environments, system architects in
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences12.3.2026 14:00:00 CET | Press release
Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. The acquisition enables Enodia to advance its understanding of Sec61 selectivity mechanisms, expanding biological and translational insights for faster progression toward key clinical milestones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312627573/en/ Under the terms of the purchase agreement between Enodia and Kezar, Kezar w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom